drugset / Trial / NCT01972776

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

NCT01972776

Phase 2 Terminated 48 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindBasic science

Summary

This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.

Timeline

Start
2013-11
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject QBM076 Unknown 25 mg
Subject QBM076 Unknown 75 mg
Subject QBM076 Unknown 150 mg